Atossa Therapeutics, Inc.
ATOS
$5.16
-$0.34-6.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.88% | 30.54% | -0.39% | 0.77% | 11.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.92% | 44.89% | 27.23% | 6.22% | -20.71% |
| Operating Income | -59.92% | -44.89% | -27.23% | -6.22% | 20.71% |
| Income Before Tax | -72.32% | -20.22% | -39.25% | -14.29% | 18.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.32% | -20.22% | -39.25% | -14.29% | 18.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.32% | -20.22% | -39.25% | -14.29% | 18.15% |
| EBIT | -59.92% | -44.89% | -27.23% | -6.22% | 20.71% |
| EBITDA | -59.96% | -44.91% | -27.25% | -6.24% | 20.63% |
| EPS Basic | -68.90% | -17.06% | -35.53% | -10.87% | 18.99% |
| Normalized Basic EPS | -68.89% | -53.29% | -35.54% | -10.89% | 18.99% |
| EPS Diluted | -68.90% | -17.06% | -35.53% | -10.87% | 18.99% |
| Normalized Diluted EPS | -68.89% | -53.29% | -35.54% | -10.89% | 18.99% |
| Average Basic Shares Outstanding | 2.02% | 2.70% | 2.74% | 3.07% | 1.05% |
| Average Diluted Shares Outstanding | 2.02% | 2.70% | 2.74% | 3.07% | 1.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |